| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NRGN |
| Uniprot No | Q92686 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-78aa |
| 氨基酸序列 | MDCCTENACSKPDDDILDIPLDDPGANAAAAKIQASFRGHMARKKIKSGE RGRKGPGPGGPGGAGVARGGAGGGPSGD |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NRGN重组蛋白的3篇参考文献示例(注：文献信息为模拟，实际需根据真实研究调整)：
---
1. **文献名称**: *Expression and Purification of Recombinant Neurogranin in E. coli for Functional Studies*
**作者**: Smith A, et al.
**摘要**: 研究报道了在大肠杆菌中高效表达和纯化重组NRGN蛋白的方法，通过优化诱导条件和纯化步骤获得高纯度蛋白，并验证其体外钙调蛋白结合活性，为神经信号机制研究提供工具。
2. **文献名称**: *Neurogranin as a Biomarker: Development of a Recombinant Protein-Based Assay for Alzheimer's Disease*
**作者**: Zhang L, et al.
**摘要**: 研究利用重组NRGN蛋白开发ELISA检测方法，分析脑脊液中NRGN水平，发现其浓度与阿尔茨海默病严重程度相关，提示其作为神经退行性疾病生物标志物的潜力。
3. **文献名称**: *Structural Insights into Recombinant Neurogranin-Calmodulin Interaction by NMR Spectroscopy*
**作者**: Lee J, et al.
**摘要**: 通过核磁共振技术解析重组NRGN蛋白的结构，揭示其与钙调蛋白的动态结合机制，阐明其在突触可塑性和学习记忆中的分子基础。
---
如需真实文献，建议在PubMed或Web of Science中检索关键词“recombinant neurogranin”或联系具体研究方向。
Neurogranin (NRGN) is a small, calmodulin-binding protein predominantly expressed in the brain, particularly in dendritic spines and postsynaptic terminals of neurons. It plays a critical role in synaptic plasticity, learning, and memory by modulating calcium-mediated signaling pathways. Structurally, it contains an IQ domain that interacts with calmodulin in a calcium-dependent manner, regulating downstream targets like protein kinase C and nitric oxide synthase. Dysregulation of neurogranin has been implicated in neurodegenerative disorders, including Alzheimer’s disease (AD), where reduced levels correlate with synaptic loss and cognitive decline. Its presence in cerebrospinal fluid (CSF) has garnered attention as a biomarker for synaptic dysfunction in early AD.
Recombinant NRGN proteins are engineered using expression systems such as *E. coli* or mammalian cells to produce purified, biologically active forms for research and diagnostic applications. These proteins retain the functional domains necessary for studying interactions with calmodulin, phosphorylation dynamics, or synaptic protein networks. Recombinant NRGN is instrumental in *in vitro* assays, antibody development for diagnostic kits, and structural studies to elucidate its role in neurodegenerative mechanisms. Recent studies also explore its potential therapeutic applications, including targeting synaptic resilience or calcium signaling pathways. However, challenges remain in ensuring proper post-translational modifications (e.g., phosphorylation) when using prokaryotic systems, often necessitating eukaryotic expression for certain functional analyses. Overall, recombinant NRGN serves as a vital tool for advancing neuroscience research and biomarker-driven diagnostics in neurodegenerative diseases.
×
